Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adbelizumab combined with irinotecan liposome or etoposide-platinum for previously treated ES-SCLC
ChiCTR2400082466Phase 2Recruiting
- Sponsor
- Shijiazhuang People's Hospital
- Start
- Mar 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of adebrelimab, irinotecan liposome, etoposide, cisplatin and carboplatin in small cell lung cancer (SCLC) (3 cohorts), sponsored by Shijiazhuang People's Hospital. Primary endpoint: overall response rate. Started Mar 2024; status: recruiting.
02
Drugs
adebrelimabirinotecan liposomeetoposidecisplatincarboplatin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400082466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082466.